Weekly Digest | Big Health Industry Investment and Financing Report (20241125)

【Radiation Therapy Drugs】Saihe Biotechnology was founded in 2024, with its founding team consisting of experts and scholars from Duke University in the United States who specialize in radiochemistry and biomedical engineering research. The company has pioneered a globally innovative technology for coupling alpha particles in nuclear medicine, establishing a new method for targeted alpha particle radiation therapy. It is developing a novel targeted delivery platform for coupling halogen-based diagnostic and therapeutic radioisotopes and their application in cancer treatment, addressing major challenges in cancer diagnosis and treatment through proprietary technology. The company will focus its product pipeline on diseases that pose significant threats to human health, such as liver cancer, pancreatic cancer, thyroid cancer, ovarian cancer, and lung cancer.

【Investor】Fir Creek Capital

【Allergy Immunotherapy】Worg is a clinical-stage biopharmaceutical company dedicated to providing breakthrough immunotherapy solutions to effectively combat allergies, autoimmune diseases, and other severe unmet medical needs. Established in 2018, the company is headquartered in Hangzhou, China, with an operational center in Basel, Europe. It leverages PCFiT technology for treating allergic rhinitis, allergic conjunctivitis, and allergic asthma; and Apitopes technology for treating multiple sclerosis, Graves' disease, uveitis, hemophilia factor VIII inhibitors, as well as other autoimmune diseases such as myocarditis and rheumatoid arthritis. Additionally, the company is actively advancing the development of its proprietary platform for molecular allergy diagnostics.

【Investor】QingSong Capital, PICC Equity

【CGT CDMO】Hangzhou Rongze Biotechnology Group Co., Ltd. was founded in 2014, focusing on the development and clinical application of cell and gene therapy technologies, the construction of human life sample banks, contract research and development services for biopharmaceuticals, regenerative medicine, and other core businesses. The company has established multiple cell and gene drug development laboratories that meet GMP standards in Shanghai, Beijing, Hangzhou, and other locations. Currently, it is developing various cell and gene therapy product pipelines targeting major diseases such as cirrhosis, cartilage defects, cancer, and congenital cardiomyopathy. The company has built several cell and gene drug development platforms, including peripheral blood mesenchymal stem cells (RZ-PBMSCs), human stem cell-like central memory T cells (RZ-TSCM), and gene base editors (RZ-Base Editor). Additionally, the company has developed innovative technology platforms for exosome product development and organoid modeling. Several of its cell drug pipelines, targeting cirrhosis, diabetic foot, and cartilage defects, have entered the clinical validation stage.

【Investor】Not disclosed

【Neurodegenerative Disease Drugs】Shanghai Braegen Pharmaceutical Co., LTD Targets the Huge Market of Neurodegenerative Diseases, Focusing on the Neuroprotective and Modulatory Effects of the BDNF-TrkB Signaling Pathway, as Well as the Role of AEP/δ-secretase in the Pathogenic Protein Cleavage in Various CNS Diseases. The company's self-developed Class I innovative drug, BrAD-R13 Tablets, has obtained clinical trial approval from both the U.S. FDA and China NMPA. It is the world’s first small-molecule TrkB receptor agonist to enter the clinical stage, intended for the treatment of mild to moderate Alzheimer’s disease, and is currently undergoing Phase I clinical trials. Another self-developed product, the Parkinson’s early diagnostic PET tracer [18F]-F0502B, has completed preclinical verification with data published in top-tier journals, gaining full recognition. It is expected to become the world’s first diagnostic radiopharmaceutical targeting the α-synuclein and serve as the objective gold standard for clinical diagnosis. It is currently undergoing investigator-led clinical trials.

【Investor】Co-creation Ventures, TusStar, CAS Star

【Protein Degradation Drugs】LeadBio Biomedical Co., Ltd. was founded in 2019 as a biopharmaceutical company dedicated to the research and development of First-in-class/Best-in-class small molecule innovative drugs. Located in Shanghai's Zhangjiang Science City, the company focuses on two therapeutic areas with significant market opportunities and synergistic effects: autoimmune diseases and oncology, leveraging Targeted Protein Degradation (TPD) drug technology as its core. The company has established the Nano-SPUD® platform for targeted intracellular protein and E3 ligase screening and development, and the Lyso-SPUD® platform for targeted extracellular protein screening and development, both based on targeted protein ubiquitination and degradation. The first pipeline developed using the proprietary Nano-SPUD® platform received official approval from the U.S. FDA in May 2023, gained formal approval from China’s NMPA in October 2023, and successfully initiated Phase 1 clinical trials in China in June 2024, completing the dosing of the first cohort of healthy subjects.

【Investor】Longpan Capital, Zhangke Lingyi, Tianrui Fennian

【Peptide Drug CDMO】Xingputai was established in September 2019 by ChemPartner, a leading AI + peptide Contract Research, Development, and Manufacturing Organization (CDMO) platform company. It brings together a senior team with extensive experience in peptide research and industrialization. The Xingputai project is located in Taixing Economic Development Zone, one of the top ten chemical industrial parks in China, with a total investment of 1.03 billion yuan and covering an area of 120 mu. The project has been included in the National Major Construction Projects Database. Xingputai integrates world-class artificial intelligence drug discovery technology and advanced green peptide synthesis processes. It has undertaken peptide innovative drug CDMO services for several well-known domestic and international pharmaceutical companies. Additionally, Xingputai has successfully developed more than 10 high-value peptide active pharmaceutical ingredients (APIs), including blockbuster products such as Semaglutide and Tirzepatide, covering multiple therapeutic areas like diabetes and weight management, anti-infective treatments, and ophthalmic diseases. Some of these products have surpassed the quality control standards of their overseas original counterparts.

【Investor】Not disclosed

【Radiopharmaceuticals CDMO】Tongrui Biologics is an innovative biopharmaceutical company focusing on the research and development, production, clinical application, and commercialization of radiopharmaceuticals. In 2021, the company invested in building a world-class radiopharmaceutical research and development center and a cGMP production base compliant with U.S. FDA, EU EMA, and China NMPA regulatory requirements within the Chengdu Medical City in China. It also obtained a Grade A Radiation Safety Permit. By collaborating with globally leading radiopharmaceutical R&D pipelines and technology platforms, the company has established key capabilities in innovative radiopharmaceutical research, development, and operations, aiming to become a leading platform enterprise in China’s radiopharmaceutical field.

【Investor】Tailong Venture Capital, Shenzhen Capital Group New Materials Fund, Guanghua Phoenix, 3SBio, Hillhouse Ventures

【Synthetic Lethal Drugs】InnoPharma is committed to developing innovative targeted anticancer drugs with proprietary intellectual property, focusing on the synthetic lethality mechanism. Based on its self-developed products in the DNA Damage Response (DDR) pathway, the company has built one of the most comprehensive DDR product portfolios among global biopharmaceutical companies and is gradually expanding into more novel synthetic lethal targets. The company's pipeline includes PARP inhibitors, WEE1 inhibitors, ATR inhibitors, PARP1 selective inhibitors, and multiple other DDR target inhibitors. The most advanced R&D project, the PARP inhibitor Senaparib (IMP4297), is currently undergoing Phase II/III clinical trials globally, including in China, for indications such as ovarian cancer and small cell lung cancer. Early data have shown superior safety and a broader therapeutic window compared to similar drugs. The Phase III clinical study (FLAMES) of Senaparib for first-line maintenance treatment in the entire population with advanced ovarian cancer has reached its primary endpoint, demonstrating best-in-class efficacy and safety. Its New Drug Application (NDA) has been accepted by the National Medical Products Administration (NMPA).

【Investor】Not disclosed

【Small-Caliber Artificial Blood Vessels】Shengna Technology (Shanghai) Co., Ltd. is a high-tech company based on advanced nanoelectrospinning technology, dedicated to the development, production, and sales of medical devices such as small-diameter artificial blood vessels and nano-functional fiber membrane materials. It is the first project introduced by the Shanghai Zhangjiang Berkeley Engineering Innovation Center from the University of California, Berkeley. The main research product is small-diameter artificial blood vessels, with the marketed product being the Shengna 3D Nanofiber Protective Mask, and other products under development include Shengna Nanofiber Solid Mask and other nano-functional fiber membrane materials.

【Investor】Fir Creek Capital

【Biodegradable Medical Metal Materials】Shangning Kezhi, founded in 2021, is a pioneer in biodegradable medical metal materials. It focuses on the research, development, and production of various novel biodegradable zinc alloy bio-implants and is committed to exploring the application of biodegradable zinc alloy technology in the medical field. Zinc alloy materials exhibit stable mechanical properties and excellent processability. Their degradation rate is controllable, and their degradation products are safe. There is no need for secondary surgery to remove the implants, reducing the risks of infection and chronic inflammation. Additionally, zinc alloys promote bone formation and tendon-bone healing. Furthermore, zinc alloys have strong imaging visibility, significantly improving the accuracy of radiological diagnostics for patients with implants. In 2023, the company launched clinical trials for two sports medicine products, marking the world's first entry of biodegradable zinc alloy technology into clinical trials.

【Investor】Investment in Pharmaceutical and Health Industry

【PET-CT】Sichuan Jiuyiyuan Particle Technology Co., Ltd. was established in February 2017 as a military-civilian integration enterprise in the field of nuclear technology applications. With scientists from the Institute of Fluid Physics at the China Academy of Engineering Physics as its core, the company is engaged in the research and manufacturing of nuclear medicine equipment. It has advanced China's high-end nuclear medicine localization process with the country’s first fully self-developed cyclotron for PET-CT. The company also provides advanced diagnostic and treatment solutions to cancer patients and high-risk populations worldwide. To date, the company has obtained multiple authoritative certifications and 40 patent authorizations, with business operations spanning numerous countries and regions globally.

【Investor】Haiwang Capital

【Surface Guided Radiation Therapy (SGRT)】Shenzhen Yangqi Yixin Intelligent Technology Co., Ltd. focuses on the precise nuclear medical field and was established in September 2021. The core founding team is composed of experts in nuclear medicine, nuclear physics, and artificial intelligence technologies from Stanford, Alibaba, and other leading institutions inside and outside China. The company's headquarters is currently located in Shenzhen, with research and development centers set up in Hangzhou, Shanghai, and other locations. It has launched multiple product development pipelines and established close cooperation with more than ten leading medical institutions and manufacturers in China. Yangqi Yixin's products primarily concentrate on the optical surface-guided radiation therapy (SGRT) field, including the optical surface monitoring product "Qishi," the low-dose CT enhancement product "Qingying," and SRT low-energy superficial radiotherapy equipment.

【Investor】Anfeng Venture Capital

【Ultrasound Diagnostic and Therapeutic Equipment】Wuxi Yisheng Micro-Nano Medical Technology Co., Ltd. was established in 2021, with its headquarters located in Wuxi. It is a high-tech company specializing in the design, research and development, and production of ultrasonic transducers. The company currently has two factories (a piezoelectric smart materials factory and a transducer intelligent manufacturing factory) and one research and development center. Its product range covers: minimally invasive interventional ultrasound catheters and transducers, external conventional imaging probes, ultrasonic scalpel booster horns, piezoelectric nozzles, ultrasound drug delivery devices, high-performance piezoelectric ceramics, single-crystal and polymer piezoelectric materials, etc.

【Investor】Cairong Ventures

【In Vitro Diagnostics】Shandong Zhonghong Tejian Biotechnology Co., Ltd. was established on July 21, 2020, focusing on the development and commercialization of innovative diagnostic kits, serving hospitals, laboratories, and research institutions worldwide. The company is committed to independent innovation, vertical integration, and global expansion, and has built a diversified product portfolio in key areas such as cytokine detection, Alzheimer's disease biomarkers, infectious disease markers, and liver cancer diagnosis. Since its market launch in 2023, the products have been successively recognized by top-tier hospitals in China, with installations reaching dozens of TOP100 medical institutions.

【Investor】Shandong Caijin Group

【AI + Protein Design】Shanghai Tianwu Technology Co., Ltd., established in 2021 by an elite team from Shanghai Jiao Tong University, is a global leading AI protein design service provider. With its self-developed general artificial intelligence for protein design, AccelProtein™, the company addresses core issues in traditional protein design paradigms such as long design cycles, high costs, low success rates, and challenges in multi-objective optimization. It has played a significant role in enhancing customer product performance, shortening R&D cycles, reducing production costs, and helping clients build high-barrier patent portfolios. Currently, the company’s technical services have expanded into multiple fields, including biopharmaceuticals, in vitro diagnostics, pharmaceutical intermediates, nutritional health, food and beverages, beauty and skincare, cleaning and textiles, bioenergy, bioagriculture, and environmental engineering, showcasing its extensive influence and technical strength in the field of protein design.

【Investor】Qiming Venture Partners, Yonghua Investment, BioTrack Capital

【AI + Synthetic Peptide Drugs】Chengyuan (Guangzhou) Technology Co., Ltd. is an innovative drug research and development enterprise incubated by Innovation Works, with artificial intelligence technology in natural language processing (NLP) at its core. Committed to accelerating the research and development of synthetic peptide drugs through AI empowerment, the company has built a leading AI + synthetic peptide drug R&D platform in the industry. This platform enables the full-chain empowerment of AI in the design, screening, synthesis, characterization, optimization, and other aspects of synthetic peptide drugs, and has been applied to the R&D of multiple global new (First in class) synthetic peptide drug pipelines.

【Investor】AstraZeneca-CICC No.1 Venture Capital, Lirun Investment

【Emotional Health Data Analysis】Beijing Dianli Lingxi Technology Co., Ltd. was established in 2018 as a national high-tech enterprise specializing in emotional health data analysis. Relying on the research achievements of top cognitive psychology expert teams both in China and abroad, combined with the technical expertise of artificial intelligence and Internet of Things expert teams, the company utilizes tools such as smart wearables and facial recognition to develop innovative emotion technology products for comprehensive multi-dimensional emotional analysis. Leveraging its proprietary intellectual property advantages, including national invention patents, the company applies emotional health data analysis in areas such as psychological testing and evaluation, and psychological intervention. It provides student mental health screening services to education bureaus and schools; offers psychological screening and mental health examination equipment to hospitals and physical examination centers; builds a "prevention + regulation + intervention" integrated mental health service system for enterprises; and constructs social psychological service information platforms and social mindset data monitoring platforms for various local governments across China.

【Investor】Not disclosed

【Medical Beauty Materials】Shanghai Moyang Biotechnology Co., Ltd. is a company dedicated to the research, development, production, sales, and consulting services of nanomedical biomaterials and absorbable Class III implant products. The company’s mid- to long-acting Moyan Microcrystal® microsphere hydrogel dermal fillers are based on the well-established human-like calcium phosphate system used in orthopedics, oral and maxillofacial surgery, neurosurgery, ophthalmology, and other fields. They incorporate the company's unique Aphranel Magic Crystal® patented porous micro-nano bio-microsphere technology and Purelsa® patented hydrogel sustained-release technology, ensuring greater safety and efficacy. The core R&D team has been researching various types of medical calcium phosphates, calcium silicates, polylactic acids, polyamino acids, polycaprolactones, as well as genetically recombinant human collagen and bone morphogenetic proteins since 2000.

【Investor】BoYuan Capital, HengXu Capital